Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank was compromised, suggesting potential "round-tripping" of capital to artificially inflate revenue [3]. - The business model of Ambry Genetics, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, raising concerns about sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, indicating operational weaknesses [3]. - These issues collectively reveal vulnerabilities in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Allegations - Following a research report from Spruce Point Capital Management that highlighted numerous concerns regarding Tempus AI's management and financial reporting, the company's stock price fell by over 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].

Group 1 - Tempus AI (NASDAQ: TEM) is characterized as a polarizing company in the health-tech sector following its high-profile IPO and significant AI-related discussions [1] Group 2 - The company is noted for its rapid rise in prominence within the health-tech industry, attracting both interest and skepticism from investors [1]

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company during the class period from August 6, 2024, to May 27, 2025 [1][2][4] Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against Tempus AI, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - Investors who purchased Tempus securities during the specified class period are encouraged to contact the law firm before August 12, 2025, to participate in the lawsuit [2] - The class has not yet been certified, meaning that potential class members are not yet represented by an attorney [3] Group 2: Allegations Against Tempus - The complaint alleges that Tempus made false and misleading statements regarding the value of various contracts, including those with related parties and self-funded agreements [4] - Concerns were raised about Tempus's joint venture with SoftBank, which was at risk of being discredited due to the appearance of "round-tripping" capital to inflate revenue [4] - The acquisition of Ambry by Tempus is highlighted as problematic due to its aggressive and potentially unethical business practices, contributing to the misleading nature of the company's public statements [4]

智通财经APP获悉，周一开盘后，人工智能科技企业Tempus AI(TEM.US)股价应声下挫逾5%。此次股价 波动源于该公司披露的最新融资计划：拟通过私募方式发行总额4亿美元的可转换优先票据，该批票据 将于2030年7月15日到期，并采取每半年计息的付息方式。值得注意的是，除到期自然偿付外，这批票 据还附带了提前转换、赎回或回购的条款设计。 不过投资者显然对股权稀释风险保持警惕，这直接反映在当日股价的承压走势中。截至发稿，Tempus AI小幅下跌，盘前股价在65美元附近震荡。 根据发行方案，具体利率水平、初始转股价格等核心条款将在最终定价环节确定。为保障发行灵活性， 公司同步授予初始承销商为期13天的超额配售权，允许其按需追加认购最多6000万美元的额外票据额 度。 对于募集资金用途，Tempus AI在公告中明确表示，本次发行净收益将主要用于三大方向：首要用途是 全额偿清现存的2.747亿美元优先担保定期贷款本息;其次将覆盖相关封顶看涨期权交易的成本支出;剩余 部分则纳入公司日常运营资金池。 市场分析人士指出，该融资方案折射出企业优化资本结构的战略意图。通过可转债这一兼具债性和股性 的融资工具，公司既可 ...

Core Viewpoint - The healthcare sector is highlighted as a critical area in the stock market, driven by the need for innovative therapies and medical technologies to address an aging population and rising chronic diseases. There are ten under-the-radar healthcare stocks identified as potential investment opportunities. Group 1: Company Highlights - **Certara**: Positioned to benefit from AI-driven transformations in medicine, providing bio-simulation software that accelerates drug development, with over 90% of novel drugs approved by the FDA since 2014 utilizing its technology [3][4]. - **Beam Therapeutics**: A clinical-stage biotech focusing on precision gene editing therapies for genetic diseases, with its lead candidate in phase 1/2 trials for sickle cell disease, showing promise for long-term growth [5][6]. - **Inspire Medical Systems**: Develops implantable devices for obstructive sleep apnea, reporting a 23% year-over-year revenue increase to $201 million, indicating strong market demand [8]. - **Insulet**: Specializes in tubeless insulin pump technology, targeting a revenue growth of 19% to 22% by 2025, with significant expansion opportunities in international markets [9]. - **Krystal Biotech**: Focuses on rare skin diseases, with its gene therapy expected to generate approximately $400 million in revenue this year, reinforcing its market position [10]. - **LifeMD**: Operates a telehealth platform with a 49% year-over-year revenue increase, driven by a partnership with Novo Nordisk, indicating potential for further growth [11]. - **Option Care Health**: Leading provider of home infusion services, positioned to benefit from the shift towards personalized healthcare [12]. - **Tempus AI**: Utilizes AI for precision medicine, projecting over 80% revenue growth this year to about $1.3 billion, highlighting its expansive data ecosystem [13]. - **TransMedics Group**: Innovates in organ transplantation with its FDA-approved Organ Care System, projecting a 30% revenue growth this year [14][15]. - **Veeva Systems**: Offers cloud-based software for life sciences, serving over 1,000 customers and positioned to capitalize on the industry's digital transformation [16].

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank was compromised, creating the appearance of "round-tripping" capital to generate revenue [3]. - The business model of Ambry Genetics, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, raising concerns about the company's financial health [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Research Report - On May 28, 2025, a research report from Spruce Point Capital Management raised multiple concerns regarding Tempus AI's management and financial reporting, resulting in a stock price drop of over 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegatio ...

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. regarding allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Tempus and certain officers and directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Tempus securities during the Class Period have until August 12, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Concerns Raised - A report by Spruce Point Capital Management on May 28, 2025, raised concerns about Tempus, including aggressive accounting and financial reporting practices [3]. - The report also highlighted that several members of Tempus's Board and executives have been associated with companies that restated financial results [3]. - Key strategic partnerships and deal announcements with AstraZeneca and Pathos AI are under scrutiny according to the report [3]. Group 3: Company Background - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [4].

Core Insights - Tempus AI (TEM) is experiencing significant growth in its Data and Services segment, with a 43.2% year-over-year revenue increase to $61.9 million in Q1 2025, driven by a 58% growth in its Insights data licensing business [1][7] - The company has secured major contracts, including a $200 million licensing agreement with AstraZeneca (AZN) and Pathos, which has increased AZN's total remaining contract value to over $1 billion [2][7] - Tempus has expanded collaborations with key pharmaceutical companies, including Illumina and Boehringer Ingelheim, enhancing its position in biomarker development and oncology applications [3][7] Financial Performance - Gross profit for Tempus outpaced revenue growth, increasing by 65.2% with only a modest 3% rise in the cost of revenues [1] - Year-to-date, Tempus AI shares have surged 102.5%, significantly outperforming the industry average growth of 18% [6] Competitive Landscape - Competitors like ICON (ICLR) and IQVIA (IQV) are also experiencing growth, but Tempus AI's performance in securing contracts and expanding its service offerings positions it favorably in the market [4][5] - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 8.47X, compared to the industry average of 5.83X, indicating a premium valuation [8]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 26, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tempus AI, Inc. ("Tempus AI" or the "Company") (NASDAQ: TEM) investors of a class action representing investors that bought securities between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"). Tempus AI investors have until August 12, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Por ...